Electra Therapeutics

Executive Summary

Electra Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer. Founded in 2017 and headquartered in South San Francisco, the company leverages a rigorous, science-driven approach to validate novel targets. Its lead candidate, ELA026, is currently being evaluated in a pivotal Phase 2/3 study for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe inflammatory condition with high unmet need. ELA026 targets SIRP to modulate innate immune responses, potentially offering a new treatment paradigm. The company's pipeline also includes preclinical programs in oncology and autoimmune diseases, though details remain limited. With a focus on validated biology and a clear clinical path for its lead asset, Electra represents a high-risk, high-reward opportunity in the biotech space. The company's ability to execute on the ELA026 trial and secure additional funding will be key to its near-term trajectory.

Upcoming Catalysts (preview)

• Q3 2026ELA026 Phase 2/3 interim data readout65% success
• Q2 2026Series B or additional financing round70% success
• Q4 2026IND filing for next pipeline candidate50% success